|
|
Article: FDA Approves Gilead's Hepsera(TM) for the Treatment of Chronic Hepatitis B; - First Nucleotide Analogue for the Treatment of Chronic Hepatitis B -.
- Article from:
- PR Newswire
- Article date:
- September 23, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- - Second Novel Gilead Antiviral Approved in Less than One Year -
FOSTER CITY, Calif., Sept. 23 /PRNewswire-FirstCall/-- Gilead Sciences today announced that it received U.S. Food and Drug Administration (FDA) approval on Friday, September 20 for its antiviral agent Hepsera(TM) (adefovir dipivoxil) for the treatment of chronic hepatitis B. The drug will be shipped to wholesalers early this week.
Hepsera, administered as an oral 10 mg tablet, is the first nucleotide analogue to receive FDA approval for the treatment of chronic hepatitis B. It works by blocking the replication of the hepatitis B virus (HBV) in the body. In clinical studies, Hepsera ...